Proactive Investors - Run By Investors For Investors
Why invest in SAR?
Sareum Holdings Plc: DEEP DIVE
OVERVIEW

Sareum Holdings primed for progress

Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
Sareum Holdings primed for progress
OVERVIEW: SAR The Big Picture
The company has two other preclinical treatments – one for autoimmune disease, the other for cancer
  • Lead drug being developed by partner Sierra Oncology

  • Data on SRA737 should be published at a leading cancer conference

  • It has two other preclinical treatments – one for autoimmune disease the other for cancer

About Sareum

Sareum Holdings PLC's (LON:SAR) most advanced programme was developed in collaboration with the Institute of Cancer Research and the CRT Pioneer Fund. It is undergoing two Phase II clinical trials conducted by licence partner Sierra Oncology. There are a further two trials planned. The drug developer has two other preclinical discoveries - focused on autoimmune disease and cancer.

SRA737

This is a checkpoint kinase 1 inhibitor, a type of drug that controls a cancer cell's response to DNA damage. Sareum’s NASDAQ-listed partner is currently refining trials of the drug following the emergence of new data. It will focus efforts on a form of ovarian cancer. This “reprioritising and enlarging” of the ongoing Phase I/II studies have meant that the publication of clinical data is now expected to take place in mid-2019. Sierra has suggested read-out will be submitted for presentation at ASCO, America’s largest cancer conference, which takes place at the end of May running into early June.

What else does Sareum have?

Earlier in the pipeline are SDC-1801, for auto-immune diseases, and SDC-1802, for cancer. Preclinical programmes have been mapped out for each discovery with the aim of getting them into the clinic in 2020. Both are members of the Janus Kinase (JAK) family and specifically are TYK2/JAK1 kinases. They work by inhibiting the activity of one or more of the Janus kinase family of enzymes.

What the broker says

Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space.”

View full SAR profile View Profile

Sareum Holdings Plc Timeline

Big Picture
February 22 2019

Related Articles

young girl with allergy
February 15 2019
Allergy Therapeutics is a long-established specialist in the prevention, diagnosis and treatment of allergies
Cyrptocurrencies
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
A paper plane about to be launched with the help of surgical scissors
November 13 2018
The voluntarily-suspended company is progressing an ongoing recapitalisation plan.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use